172348-63-9

Usage

Uses

Used in Pharmaceutical Industry:
Trans-4-(Boc-aMinoMethyl)cyclohexaneMethanol, 97% is used as an intermediate in the synthesis of various drugs and pharmaceutical compounds. The presence of the Boc protective group allows for selective protection of amines during chemical reactions, facilitating the synthesis of complex organic molecules.
Used in Chemical Industry:
Trans-4-(Boc-aMinoMethyl)cyclohexaneMethanol, 97% is used as a building block in the preparation of various organic compounds. The cyclohexane ring and hydroxyl group in the molecule provide opportunities for modification and functionalization, enabling the development of new chemical entities with diverse properties and applications.

Upstream product

• 27687-14-5 trans 4-(tert-butyloxycarbonylamino)methylcyclohexanecarboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 178972-33-3 trans-4-(aminomethyl)cyclohexanemethanol hydrochloride 
• 1197-18-8 trans-4-aminomethyl-cyclohexyl-carboxylic acid 

Downstream Products

• 178972-34-4 toluene-4-sulfonic acid 4-(tert-butoxycarbonylamino-methyl)-cyclohexylmethyl ester 
• 192323-08-3 N-tert-butoxycarbonyl-trans-4-(aminomethyl)cyclohexanemethyl azide 
• 853799-80-1 [4-(quinazolin-2-ylaminomethyl)-cyclohexylmethyl]-carbamic acid tert-butyl ester 
• 192323-09-4 {4-[(4-amino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-carbamic acid tert-butyl ester 
• 509142-38-5 {4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-carbamic acid tert-butyl ester 
• 166168-16-7 trans-((4-aminomethyl)cyclohexylmethyl)carbamic acid tert-butyl ester 
• 749866-16-8 4-amino-2-[trans-(4-aminomethylcyclohexyl)methyamino]quinazoline 
• 1187857-60-8 ethyl 2-(((1r,4r)-4-((tert-butoxycarbonylamino)methyl)cyclohexyl)methoxy)acetate 
• 1187857-15-3 tert-butyl 2-(((1r,4r)-4-((tert-butoxycarbonylamino)methyl)cyclohexyl)methoxy)acetate 
• 1187857-61-9 ethyl 2-(((1r,4r)-4-(aminomethyl)cyclohexyl)methoxy)acetate 
• 1187857-14-2 2-(((1r,4r)-4-((3,3-diphenylureido)methyl)cyclohexyl)methoxy)acetic acid 
• 1187857-16-4 2-(((1r,4r)-4-((3-benzhydrylureido)methyl)cyclohexyl)methoxy)acetic acid 
• 1187856-37-6 2-(((1r,4r)-4-((3-benzhydryl-3-methylureido)methyl)cyclohexyl)methoxy)acetic acid 
• 1187857-17-5 2-(((1r,4r)-4-((3-(3-methoxyphenyl)-3-phenylureido)methyl)cyclohexyl)methoxy)acetic acid 

Relevant academic research and scientific papers

METALLO-BETA-LACTAMASE INHIBITORS

The present invention relates to compounds of formula (I) that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.

Discovery of 4-(dimethylamino)quinazolines as potent and selective antagonists for the melanin-concentrating hormone receptor 1

A series of 4-(dimethylamino)quinazoline based antagonists of the melanin-concentrating hormone receptor 1 (MCH-R1) is described. This series was derived from a lead compound, AR129330, identified by HTS of a GPCR-directed library using a functional assay with a constitutively activated (CART) form of the receptor. The preliminary optimization resulted in the identification of compounds 20, 21, and 23.

Development of Irreversible Diphenyl Phosphonate Inhibitors for Urokinase Plasminogen Activator

In this letter we report the synthesis and biochemical evaluation of selective, irreversible diphenyl phosphonate inhibitors for urokinase plasminogen activator (uPA). A diphenyl phosphonate group was introduced on the substratelike peptide Z-D-Ser-Ala-Arg, and modification of the guanidine side chain was investigated. A guanylated benzyl group appeared the most promising side chain modification. A kapp value in the 103 M -1 s-1 range for uPA was obtained, together with a selectivity index higher than 240 toward other trypsin-like proteases such as tPA, thrombin, plasmin, and FXa.

Fused imidazopyridine derivatives as antihyperlipidemic agents

A novel compound of the formula: wherein ring Q is an optionally substituted pyridine ring; One of R0, R1and R2is —Y0—Z0, and the other tow groups are a hydrogen, a halogen, an optionally substituted hydroxy group, a hydrocarbon group that may be an optionally substituted hydrocarbon group or an acyl group; Y0is a bond or an optionally substituted bivalent hydrocarbon group; Z0is a basic group which may be bonded via oxygen, nitrogen, —CO—, —CS—, —SO2N(R3)— (where R3is hydrogen or an optionally substituted hydrocarbon group), or S(O)n(wherein n is to 0, 1 or 2); .........is a single bond or a double bond, or a salt thereof, which has an excellent LDL receptor up-regulating, blood-lipids lowering, blood-sugar lowering and diabetic complication-ameliorating activity.

Compositions and methods for treating mast-cell mediated conditions

Novel compounds, compositions and methods effective for the prevention and treatment of mast-cell mediated inflammatory disorders are described. The compounds, compositions and methods are effective for the prevention and treatment of inflammatory diseases associated with the respiratory tract, such as asthma and allergic rhinitis, as well as other types of immunomediated inflammatory disorders, such as rheumatoid arthritis, conjunctivitis and inflammatory bowel disease, various dermatological conditions, as well as certain viral conditions. The compounds comprise potent and selective inhibitors of the mast cell protease tryptase. The compositions for treating these conditions include oral, inhalant, topical and parenteral preparations as well as devices comprising such preparations.